Abstracts tagged "psoriasis and epidemiology"

Abstract Number: 1086 • 2019 ACR/ARP Annual Meeting
Psoriatic Arthritis – Epidemiology, Incidence Rate in Psoriasis Patients, Comorbidity Profiles and Risk Factor Analysis
Jürgen Rech¹, Michael Sticherling ², Mona Biermann ³, Benjamin Häberle ³ and Maximilian Reinhardt ⁴, ¹Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany, ²Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany, Erlangen, Bayern, Germany, ³Medical Affairs, Novartis Pharma GmbH, Nürnberg, Germany, Nürnberg, Bayern, Germany, ⁴Medical Affairs, Novartis Pharma GmbH, Nürnberg, Germany, Nürnberg, Germany
Background/Purpose: Psoriasis (PsO) is a systemic inflammatory disease accompanied by comorbidities such as depression, cardiovascular diseases or metabolic syndrome. Approximately 10 - 27% of PsO…
Abstract Number: 2852 • 2019 ACR/ARP Annual Meeting
Shared and Differing Risk Factors for PsA, Psoriasis, AS, and RA: A Series of Case-control Studies
Alexis Ogdie¹, Xingmei Wang ¹, Thorvardur J Love ², Telma Thrastardottir ³, Maureen Dubreuil ⁴ and Joel Gelfand ⁵, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ³University of Iceland, Reykjavik, Iceland, ⁴Boston University School of Medicine, Boston, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: While a handful of clinical risk factors for the development of inflammatory diseases have been identified, to date, no studies have compared risk factors…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].